Sinovac Biotech
SVA
Sinovac Biotech (SVA) news
Recent news
Sinovac H1 gross profit USD 95.536 million
AInvest Wire · Aug 17, 2026Sinovac H1 pretax profit USD -69.839 million
Sinovac Biotech Ltd. (NASDAQ: SVA) reported unaudited financial results for the first half of 2023, revealing a pretax loss of USD -69.839 million for the six months ended June 30, 2023, compared to pretax income of USD 926.408 million in the same period in 2022. This decline was primarily…
AInvest Wire · Aug 17, 2026Sinovac reports unaudited first half of 2026 financial results
AInvest Wire · Aug 17, 2026Sinovac H1 basic EPS USD -0.84
AInvest Wire · Aug 17, 2026Sinovac H1 operating expenses USD 213.578 million
AInvest Wire · Aug 17, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.